|
Post by Penny on Dec 14, 2009 14:46:42 GMT -5
www.genengnews.com/news/bnitem.aspx?name=70494137Bristol-Myers Squibb (BMS) is paying Tranzyme Pharma $10 million up front as part of a collaboration to discover and develop novel macrocyclic compounds against multi BMS targets in different therapeutic areas. Tranzyme will also receive $3–6 million in research fees over the initial two-year term of the agreement plus development and regulatory milestones as well as sales royalties... (click the link to read the entire article)
|
|